Herbal preparations and “natural” dietary supplements are frequently used by patients with cardiovascular disease – often in the hope of “gently” influencing blood pressure, lipids or symptoms. However, guidelines from European and American professional societies unanimously emphasize that phytotherapeutics and dietary supplements should not replace established lifestyle and pharmacotherapy. In particular, the 2025 focused ESC/EAS update on dyslipidemia therapy concludes, after reviewing the available evidence, that there is insufficient evidence for any supplement that lowers LDL cholesterol while improving cardiovascular risk with reasonable safety.
Autoren
- Tanja Schliebe
Publikation
- PHYTOTHERAPIE PRAXIS
Related Topics
You May Also Like
- Neuroprotection, resilience and cognitive health in old age
Longevity & Brain
- Obesity as a chronic disease: an interdisciplinary perspective
Neurobiological mechanisms of obesity
- Oncolytic virus in stage II melanoma
Innovative method for predicting therapy response
- Phimosis and penile cancer under SGLT2i
Increased risk for men with T2D
- Diabetic ketoacidosis
Recommendations for action in practice
- Migraine: better quality of life thanks to multimodal care
Broader selection of innovative migraine prophylactics and acute therapies
- Therapy of non-tumor-related pain
Do not prescribe opioids lightly for musculoskeletal pain
- "Forgotten axis" between plant substances, gut and systemic health